The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Psoriasis-Pipeline Review, H2 2017

Psoriasis-Pipeline Review, H2 2017

Publishing Date : Sep, 2017

License Type :

Report Code : 768473

No of Pages : 673

Synopsis
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriasis - Pipeline Review, H2 2017, provides an overview of the Psoriasis (Immunology) pipeline landscape.

Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared up skin, itchiness, and burning sensation, swollen and stiff joints. Predisposing factors include heredity, side effects of certain medicines, stress, infections and environmental conditions. The condition may be controlled by topical or systemic medications and phototherapy.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriasis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Psoriasis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Psoriasis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Psoriasis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Psoriasis (Immunology)

Reasons To Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Psoriasis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Psoriasis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psoriasis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Psoriasis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psoriasis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 19, 1, 20, 44, 44, 2, 106, 30 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 6 molecules, respectively.

Psoriasis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Companies Mentioned
3SBio Inc
AbbVie Inc
Abeome Corp
AbGenomics International Inc
Adello Biologics LLC
Affibody AB
Albireo Pharma Inc
Alfacyte Ltd
Allergan Plc
Almirall SA
Alteogen Inc
Amgen Inc
AnaptysBio Inc
ApoPharma Inc
Arbor Pharmaceuticals LLC
Arrien Pharmaceuticals LLC
AstraZeneca Plc
Athenex Inc
Atlantic Bio Sci LLC
Aurigene Discovery Technologies Ltd
Aurinia Pharmaceuticals Inc
Baliopharm AG
Bayer AG
Beta Pharma Inc
BioApex sro
Biocad
Biocon Ltd
BioLingus AG
Bionomics Ltd
Bionovis SA
BirchBioMed Inc
Boehringer Ingelheim GmbH
Brickell Biotech Inc
Bristol-Myers Squibb Company
C4X Discovery Holdings PLC
CalciMedica Inc
Can-Fite BioPharma Ltd
Celgene Corp
ChemoCentryx Inc
Chipscreen Biosciences Ltd
ChironWells GmbH
Coherus BioSciences Inc
Compugen Ltd
Concenter BioPharma Silkim Ltd
conoGenetix biosciences GmbH
Crescita Therapeutics Inc
Dermala Inc
Dr. August Wolff GmbH & Co KG Arzneimittle
DURECT Corp
EA Pharma Co Ltd
Eli Lilly and Company
ELORAC Inc
Exicure Inc
Foamix Pharmaceuticals Ltd
Formycon AG
Forward Pharma AS
Fresenius SE & Co KGaA
Galapagos NV
Galderma SA
Galectin Therapeutics Inc
Gem Pharmaceuticals LLC
Genentech Inc
Genfit SA
Genor BioPharma Co Ltd
GlaxoSmithKline Plc
GlycoMar Ltd
Grupo Ferrer Internacional SA
HitGen LTD
Huabo Biopharm Co Ltd
Hydra Biosciences Inc
iCo Therapeutics Inc.
Immune Pharmaceuticals Inc
Immune Response BioPharma Inc
Immungenetics AG
Immunwork Inc
Innovation Pharmaceuticals Inc
Istesso Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Just Biotherapeutics Inc
Kadmon Corp LLC
Kang Stem Biotech Co Ltd
KPI Therapeutics Inc
Kymab Ltd
Lead Pharma Holding BV
LEO Pharma A/S
Lupin Ltd
Lycera Corp
mAbxience SA
Maruho Co Ltd
Medestea Research & Production SpA
MediGene AG
Merck KGaA
MetrioPharm AG
Mitsubishi Tanabe Pharma Corp
Momenta Pharmaceuticals Inc
Mycenax Biotech Inc
Nimbus Therapeutics LLC
NovaLead Pharma Pvt Ltd
Novan Inc
Novartis AG
Nuevolution AB
Numab Innovation AG
Oncobiologics Inc
Orphagen Pharmaceuticals Inc
Panacea Biotec Ltd
Pfizer Inc
Pharis Biotec GmbH
Pharmedartis GmbH
Phenex Pharmaceuticals AG
Philogen SpA
PinCell srl
Principia Biopharma Inc
Promius Pharma LLC
Protalix BioTherapeutics Inc
Prothena Corp Plc
Provectus Biopharmaceuticals Inc
Qilu Pharmaceutical Co Ltd
RedHill Biopharma Ltd
Reliance Life Sciences Pvt Ltd
Rigel Pharmaceuticals Inc
Samumed LLC
Sandoz International GmbH
Sareum Holdings Plc
SBI Biotech Co Ltd
Shulov Innovative Science Ltd
Sienna Biopharmaceuticals Inc
Sigmoid Pharma Ltd
Soligenix Inc
Spherium Biomed SL
Stemline Therapeutics Inc
sterna biologicals Gmbh & Co KG
Sun Pharma Advanced Research Company Ltd
Switch Biotech LLC
Syntrix Biosystems Inc
Tasly Pharmaceutical Group Co Ltd
Teva Pharmaceutical Industries Ltd
TheraMAB LLC
Tolero Pharmaceuticals Inc
UCB SA
Valeant Pharmaceuticals International Inc
Vicore Pharma AB
vTv Therapeutics Inc
Wellstat Therapeutics Corp
XBiotech Inc
Yuhan Corp
Index
Table of Contents
Table of Contents 2
Introduction 8
Psoriasis - Overview 9
Psoriasis - Therapeutics Development 10
Psoriasis - Therapeutics Assessment 41
Psoriasis - Companies Involved in Therapeutics Development 57
Psoriasis - Drug Profiles 120
Psoriasis - Dormant Projects 613
Psoriasis - Discontinued Products 629
Psoriasis - Product Development Milestones 632
Appendix 644
List of Tables
List of Tables
Number of Products under Development for Psoriasis, H2 2017 38
Number of Products under Development by Companies, H2 2017 40
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 41
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 42
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 43
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 44
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 45
Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 46
Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017 47
Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017 48
Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017 49
Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017 50
Number of Products under Development by Universities/Institutes, H2 2017 51
Products under Development by Companies, H2 2017 52
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 53
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 54
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 55
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 56
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 57
Products under Development by Companies, H2 2017 (Contd..6), H2 2017 58
Products under Development by Companies, H2 2017 (Contd..7), H2 2017 59
Products under Development by Companies, H2 2017 (Contd..8), H2 2017 60
Products under Development by Companies, H2 2017 (Contd..9), H2 2017 61
Products under Development by Companies, H2 2017 (Contd..10), H2 2017 62
Products under Development by Companies, H2 2017 (Contd..11), H2 2017 63
Products under Development by Companies, H2 2017 (Contd..12), H2 2017 65
Products under Development by Companies, H2 2017 (Contd..13), H2 2017 66
Products under Development by Companies, H2 2017 (Contd..14), H2 2017 67
Products under Development by Universities/Institutes, H2 2017 68
Number of Products by Stage and Target, H2 2017 70
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 71
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 72
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 73
Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 74
Number of Products by Stage and Mechanism of Action, H2 2017 76
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 77
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 78
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 79
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 80
Number of Products by Stage and Route of Administration, H2 2017 82
Number of Products by Stage and Molecule Type, H2 2017 84
Psoriasis - Pipeline by 3SBio Inc, H2 2017 85
Psoriasis - Pipeline by AbbVie Inc, H2 2017 86
Psoriasis - Pipeline by Abeome Corp, H2 2017 86
Psoriasis - Pipeline by AbGenomics International Inc, H2 2017 86
Psoriasis - Pipeline by Adello Biologics LLC, H2 2017 87
Psoriasis - Pipeline by Affibody AB, H2 2017 87
Psoriasis - Pipeline by Albireo Pharma Inc, H2 2017 88
Psoriasis - Pipeline by Alfacyte Ltd, H2 2017 88
Psoriasis - Pipeline by Allergan Plc, H2 2017 88
Psoriasis - Pipeline by Almirall SA, H2 2017 89
Psoriasis - Pipeline by Alteogen Inc, H2 2017 89
Psoriasis - Pipeline by Amgen Inc, H2 2017 90
Psoriasis - Pipeline by AnaptysBio Inc, H2 2017 90
Psoriasis - Pipeline by ApoPharma Inc, H2 2017 91
Psoriasis - Pipeline by Arbor Pharmaceuticals LLC, H2 2017 91
Psoriasis - Pipeline by Arrien Pharmaceuticals LLC, H2 2017 91
Psoriasis - Pipeline by AstraZeneca Plc, H2 2017 92
Psoriasis - Pipeline by Athenex Inc, H2 2017 92
Psoriasis - Pipeline by Atlantic Bio Sci LLC, H2 2017 93
Psoriasis - Pipeline by Aurigene Discovery Technologies Ltd, H2 2017 93
Psoriasis - Pipeline by Aurinia Pharmaceuticals Inc, H2 2017 94
Psoriasis - Pipeline by Baliopharm AG, H2 2017 94
Psoriasis - Pipeline by Bayer AG, H2 2017 94
Psoriasis - Pipeline by Beta Pharma Inc, H2 2017 95
Psoriasis - Pipeline by BioApex sro, H2 2017 95
Psoriasis - Pipeline by Biocad, H2 2017 96
Psoriasis - Pipeline by Biocon Ltd, H2 2017 96
Psoriasis - Pipeline by BioLingus AG, H2 2017 97
Psoriasis - Pipeline by Bionomics Ltd, H2 2017 97
Psoriasis - Pipeline by Bionovis SA, H2 2017 97
Psoriasis - Pipeline by BirchBioMed Inc, H2 2017 98
Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H2 2017 98
Psoriasis - Pipeline by Brickell Biotech Inc, H2 2017 99
Psoriasis - Pipeline by Bristol-Myers Squibb Company, H2 2017 99
Psoriasis - Pipeline by C4X Discovery Holdings PLC, H2 2017 100
Psoriasis - Pipeline by CalciMedica Inc, H2 2017 100
Psoriasis - Pipeline by Can-Fite BioPharma Ltd, H2 2017 100
Psoriasis - Pipeline by Celgene Corp, H2 2017 101
Psoriasis - Pipeline by ChemoCentryx Inc, H2 2017 101
Psoriasis - Pipeline by Chipscreen Biosciences Ltd, H2 2017 102
Psoriasis - Pipeline by ChironWells GmbH, H2 2017 102
Psoriasis - Pipeline by Coherus BioSciences Inc, H2 2017 103
Psoriasis - Pipeline by Compugen Ltd, H2 2017 103
Psoriasis - Pipeline by Concenter BioPharma Silkim Ltd, H2 2017 103
Psoriasis - Pipeline by conoGenetix biosciences GmbH, H2 2017 104
Psoriasis - Pipeline by Crescita Therapeutics Inc, H2 2017 104
Psoriasis - Pipeline by Dermala Inc, H2 2017 105
Psoriasis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H2 2017 105
Psoriasis - Pipeline by DURECT Corp, H2 2017 106
Psoriasis - Pipeline by EA Pharma Co Ltd, H2 2017 106
Psoriasis - Pipeline by Eli Lilly and Company, H2 2017 106
Psoriasis - Pipeline by ELORAC Inc, H2 2017 107
Psoriasis - Pipeline by Exicure Inc, H2 2017 107
Psoriasis - Pipeline by Foamix Pharmaceuticals Ltd, H2 2017 108
Psoriasis - Pipeline by Formycon AG, H2 2017 108
Psoriasis - Pipeline by Forward Pharma AS, H2 2017 109
Psoriasis - Pipeline by Fresenius SE & Co KGaA, H2 2017 109
Psoriasis - Pipeline by Galapagos NV, H2 2017 110
Psoriasis - Pipeline by Galderma SA, H2 2017 110
Psoriasis - Pipeline by Galectin Therapeutics Inc, H2 2017 110
Psoriasis - Pipeline by Gem Pharmaceuticals LLC, H2 2017 111
Psoriasis - Pipeline by Genentech Inc, H2 2017 111
Psoriasis - Pipeline by Genfit SA, H2 2017 112
Psoriasis - Pipeline by Genor BioPharma Co Ltd, H2 2017 112
Psoriasis - Pipeline by GlaxoSmithKline Plc, H2 2017 113
Psoriasis - Pipeline by GlycoMar Ltd, H2 2017 113
Psoriasis - Pipeline by Grupo Ferrer Internacional SA, H2 2017 113
Psoriasis - Pipeline by HitGen LTD, H2 2017 114
Psoriasis - Pipeline by Huabo Biopharm Co Ltd, H2 2017 114
Psoriasis - Pipeline by Hydra Biosciences Inc, H2 2017 114
Psoriasis - Pipeline by iCo Therapeutics Inc., H2 2017 115
Psoriasis - Pipeline by Immune Pharmaceuticals Inc, H2 2017 115
Psoriasis - Pipeline by Immune Response BioPharma Inc, H2 2017 116
Psoriasis - Pipeline by Immungenetics AG, H2 2017 116
Psoriasis - Pipeline by Immunwork Inc, H2 2017 116
Psoriasis - Pipeline by Innovation Pharmaceuticals Inc, H2 2017 117
Psoriasis - Pipeline by Istesso Ltd, H2 2017 117
Psoriasis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 118
Psoriasis - Pipeline by Johnson & Johnson, H2 2017 118
Psoriasis - Pipeline by Just Biotherapeutics Inc, H2 2017 119
Psoriasis - Pipeline by Kadmon Corp LLC, H2 2017 119
Psoriasis - Pipeline by Kang Stem Biotech Co Ltd, H2 2017 119
Psoriasis - Pipeline by KPI Therapeutics Inc, H2 2017 120
Psoriasis - Pipeline by Kymab Ltd, H2 2017 120
Psoriasis - Pipeline by Lead Pharma Holding BV, H2 2017 121
Psoriasis - Pipeline by LEO Pharma A/S, H2 2017 121
Psoriasis - Pipeline by Lupin Ltd, H2 2017 122
Psoriasis - Pipeline by Lycera Corp, H2 2017 122
Psoriasis - Pipeline by mAbxience SA, H2 2017 122
Psoriasis - Pipeline by Maruho Co Ltd, H2 2017 123
Psoriasis - Pipeline by Medestea Research & Production SpA, H2 2017 123
Psoriasis - Pipeline by MediGene AG, H2 2017 124
Psoriasis - Pipeline by Merck KGaA, H2 2017 124
Psoriasis - Pipeline by MetrioPharm AG, H2 2017 124
Psoriasis - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017 125
Psoriasis - Pipeline by Momenta Pharmaceuticals Inc, H2 2017 125
Psoriasis - Pipeline by Mycenax Biotech Inc, H2 2017 126
Psoriasis - Pipeline by Nimbus Therapeutics LLC, H2 2017 126
Psoriasis - Pipeline by NovaLead Pharma Pvt Ltd, H2 2017 127
Psoriasis - Pipeline by Novan Inc, H2 2017 127
Psoriasis - Pipeline by Novartis AG, H2 2017 128
Psoriasis - Pipeline by Nuevolution AB, H2 2017 128
Psoriasis - Pipeline by Numab Innovation AG, H2 2017 129
Psoriasis - Pipeline by Oncobiologics Inc, H2 2017 129
Psoriasis - Pipeline by Orphagen Pharmaceuticals Inc, H2 2017 129
Psoriasis - Pipeline by Panacea Biotec Ltd, H2 2017 130
Psoriasis - Pipeline by Pfizer Inc, H2 2017 130
Psoriasis - Pipeline by Pharis Biotec GmbH, H2 2017 131
Psoriasis - Pipeline by Pharmedartis GmbH, H2 2017 131
Psoriasis - Pipeline by Phenex Pharmaceuticals AG, H2 2017 132
Psoriasis - Pipeline by Philogen SpA, H2 2017 132
Psoriasis - Pipeline by PinCell srl, H2 2017 132
Psoriasis - Pipeline by Principia Biopharma Inc, H2 2017 133
Psoriasis - Pipeline by Promius Pharma LLC, H2 2017 133
Psoriasis - Pipeline by Protalix BioTherapeutics Inc, H2 2017 133
Psoriasis - Pipeline by Prothena Corp Plc, H2 2017 134
Psoriasis - Pipeline by Provectus Biopharmaceuticals Inc, H2 2017 134
Psoriasis - Pipeline by Qilu Pharmaceutical Co Ltd, H2 2017 135
Psoriasis - Pipeline by RedHill Biopharma Ltd, H2 2017 135
Psoriasis - Pipeline by Reliance Life Sciences Pvt Ltd, H2 2017 136
Psoriasis - Pipeline by Rigel Pharmaceuticals Inc, H2 2017 136
Psoriasis - Pipeline by Samumed LLC, H2 2017 137
Psoriasis - Pipeline by Sandoz International GmbH, H2 2017 137
Psoriasis - Pipeline by Sareum Holdings Plc, H2 2017 137
Psoriasis - Pipeline by SBI Biotech Co Ltd, H2 2017 138
Psoriasis - Pipeline by Shulov Innovative Science Ltd, H2 2017 138
Psoriasis - Pipeline by Sienna Biopharmaceuticals Inc, H2 2017 139
Psoriasis - Pipeline by Sigmoid Pharma Ltd, H2 2017 139
Psoriasis - Pipeline by Soligenix Inc, H2 2017 140
Psoriasis - Pipeline by Spherium Biomed SL, H2 2017 140
Psoriasis - Pipeline by Stemline Therapeutics Inc, H2 2017 140
Psoriasis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2017 141
Psoriasis - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 141
Psoriasis - Pipeline by Switch Biotech LLC, H2 2017 142
Psoriasis - Pipeline by Syntrix Biosystems Inc, H2 2017 142
Psoriasis - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017 143
Psoriasis - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017 143
Psoriasis - Pipeline by TheraMAB LLC, H2 2017 143
Psoriasis - Pipeline by Tolero Pharmaceuticals Inc, H2 2017 144
Psoriasis - Pipeline by UCB SA, H2 2017 144
Psoriasis - Pipeline by Valeant Pharmaceuticals International Inc, H2 2017 145
Psoriasis - Pipeline by Vicore Pharma AB, H2 2017 145
Psoriasis - Pipeline by vTv Therapeutics Inc, H2 2017 146
Psoriasis - Pipeline by Wellstat Therapeutics Corp, H2 2017 146
Psoriasis - Pipeline by XBiotech Inc, H2 2017 147
Psoriasis - Pipeline by Yuhan Corp, H2 2017 147
Psoriasis - Dormant Projects, H2 2017 641
Psoriasis - Dormant Projects, H2 2017 (Contd..1), H2 2017 642
Psoriasis - Dormant Projects, H2 2017 (Contd..2), H2 2017 643
Psoriasis - Dormant Projects, H2 2017 (Contd..3), H2 2017 644
Psoriasis - Dormant Projects, H2 2017 (Contd..4), H2 2017 645
Psoriasis - Dormant Projects, H2 2017 (Contd..5), H2 2017 646
Psoriasis - Dormant Projects, H2 2017 (Contd..6), H2 2017 647
Psoriasis - Dormant Projects, H2 2017 (Contd..7), H2 2017 648
Psoriasis - Dormant Projects, H2 2017 (Contd..8), H2 2017 649
Psoriasis - Dormant Projects, H2 2017 (Contd..9), H2 2017 650
Psoriasis - Dormant Projects, H2 2017 (Contd..10), H2 2017 651
Psoriasis - Dormant Projects, H2 2017 (Contd..11), H2 2017 652
Psoriasis - Dormant Projects, H2 2017 (Contd..12), H2 2017 653
Psoriasis - Dormant Projects, H2 2017 (Contd..13), H2 2017 654
Psoriasis - Dormant Projects, H2 2017 (Contd..14), H2 2017 655
Psoriasis - Dormant Projects, H2 2017 (Contd..15), H2 2017 656
Psoriasis - Discontinued Products, H2 2017 657
Psoriasis - Discontinued Products, H2 2017 (Contd..1), H2 2017 658
Psoriasis - Discontinued Products, H2 2017 (Contd..2), H2 2017 659

List of Figures
List of Figures
Number of Products under Development for Psoriasis, H2 2017 38
Number of Products under Development by Companies, H2 2017 39
Number of Products under Development by Universities/Institutes, H2 2017 51
Number of Products by Top 10 Targets, H2 2017 69
Number of Products by Stage and Top 10 Targets, H2 2017 69
Number of Products by Top 10 Mechanism of Actions, H2 2017 75
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 75
Number of Products by Routes of Administration, H2 2017 81
Number of Products by Stage and Routes of Administration, H2 2017 81
Number of Products by Top 10 Molecule Types, H2 2017 83
Number of Products by Stage and Top 10 Molecule Types, H2 2017 83

Published By : Global Markets Direct